Alexandra A. Korotaeva
Research Subjects
Alexandra A. Korotaeva has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Elena V. Samoilova
Chazov National Medical Research Center of Cardiology
9 shared publications - Igor V. Zhirov
E.I. Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
6 shared publications - Svetlana N. Nasonova
Chazov National Medical Research Center of Cardiology
6 shared publications - Sergey Tereshchenko
Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
5 shared publications A. G. Fesenko
3 shared publicationsD. A. Chepurnova
National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation, Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 2 May 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (4) , 226-230
Interleukin-1 activity regulators in acute decompensated heart failure: dependence on obesity degree
Aim. To assess the circulating levels of IL-1 and its activity regulators, IL-1Ra and IL-1R2, in patients with acute decompensated heart failure (ADHF) depending on body mass index (BMI). Materials and methods. The study included 159 patients hospitalized for ADHF. Depending on the BMI, the patients were assigned to 5 groups. The first group included 30 patients with healthy weight (BMI25 kg/m2), the second – 50 overweight patients (25≤BMI30 kg/m2), the third – 38 patients with class I obesity (30≤BMI35 kg/m2), the fourth – 28 patients with class II obesity (35≤BMI40 kg/m2), the fifth group – 13 patients with class III obesity (BMI≥40 kg/m2). Results. With increasing BMI, IL-1 levels increased, while IL-1R2 levels, on the contrary, decreased, but no statistically significant differences were found. IL-1Ra concentrations changed ambiguously and had U-shaped dependence. IL-1Ra levels were lower in overweight patients than in normal weight and obese groups. At the same time, the increase in obesity was accompanied by higher IL-1Ra levels. The highest IL-1Ra value was observed at a BMI≥40 kg/m2. Conclusion. In ADHF an increase in obesity is accompanied by an increase in the inhibition of IL-1 activity, which may be one of the mechanisms by which adipose tissue exerts a protective effect.
- 2 May 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (4) , 226-230
Open AccessInterleukin-1 activity regulators in acute decompensated heart failure: dependence on obesity degree
Aim. To assess the circulating levels of IL-1 and its activity regulators, IL-1Ra and IL-1R2, in patients with acute decompensated heart failure (ADHF) depending on body mass index (BMI). Materials and methods. The study included 159 patients hospitalized for ADHF. Depending on the BMI, the patients were assigned to 5 groups. The first group included 30 patients with healthy weight (BMI25 kg/m2), the second – 50 overweight patients (25≤BMI30 kg/m2), the third – 38 patients with class I obesity (30≤BMI35 kg/m2), the fourth – 28 patients with class II obesity (35≤BMI40 kg/m2), the fifth group – 13 patients with class III obesity (BMI≥40 kg/m2). Results. With increasing BMI, IL-1 levels increased, while IL-1R2 levels, on the contrary, decreased, but no statistically significant differences were found. IL-1Ra concentrations changed ambiguously and had U-shaped dependence. IL-1Ra levels were lower in overweight patients than in normal weight and obese groups. At the same time, the increase in obesity was accompanied by higher IL-1Ra levels. The highest IL-1Ra value was observed at a BMI≥40 kg/m2. Conclusion. In ADHF an increase in obesity is accompanied by an increase in the inhibition of IL-1 activity, which may be one of the mechanisms by which adipose tissue exerts a protective effect.
- 28 December 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (11) , 67-70
Interleukin-1 Signalling Inhibitors in Heart Failure With Preserved and Reduced Ejection Fraction
Aim To assess circulating levels of interleukin 1 (IL-1), soluble IL-1 receptor type II (sIL-1R2) and IL-1 receptor antagonist (IL-1Ra) in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in acute decompensated heart failure (ADHF) and in stable condition. Material and methods The study included 42 patients with HFpEF and 117 patients with HFrEF admitted for ADHF. After 12 months of follow-up, 31 patients with HFpEF and 84 patients with HFrEF were re-examined. Their condition was assessed as clinically stable. Plasma concentrations of IL-1, IL-1R2, and IL-1Ra were measured in all patients. Results In ADHF, IL-1R2 and IL-1Ra concentrations were higher than in stable condition, with IL-1Ra concentrations increasing markedly (3.5 times). Depending on the left ventricular ejection fraction, IL-1 was lower in patients with HFpEF, while IL-1R2 and IL-1Ra were higher than in patients with HFrEF. IL-1 was not detected in stable condition, and differences in IL-1R2 and IL-1Ra concentrations between fractions subsided. Conclusion In ADHF, the differences in the concentrations of IL-1 and endogenous inhibitors of IL-1 signaling, IL-1R2 and IL-1βRa, in patients with HFpEF and HFrEF indicated different severity of the inflammatory response in these fractions and more intense neutralization of IL-1 in patients with HFpEF compared to patients with HFrEF, which should be taken into account in the therapeutic blockade of IL-1.
- 28 December 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (11) , 67-70
Interleukin-1 Signalling Inhibitors in Heart Failure With Preserved and Reduced Ejection Fraction
Aim To assess circulating levels of interleukin 1 (IL-1), soluble IL-1 receptor type II (sIL-1R2) and IL-1 receptor antagonist (IL-1Ra) in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in acute decompensated heart failure (ADHF) and in stable condition. Material and methods The study included 42 patients with HFpEF and 117 patients with HFrEF admitted for ADHF. After 12 months of follow-up, 31 patients with HFpEF and 84 patients with HFrEF were re-examined. Their condition was assessed as clinically stable. Plasma concentrations of IL-1, IL-1R2, and IL-1Ra were measured in all patients. Results In ADHF, IL-1R2 and IL-1Ra concentrations were higher than in stable condition, with IL-1Ra concentrations increasing markedly (3.5 times). Depending on the left ventricular ejection fraction, IL-1 was lower in patients with HFpEF, while IL-1R2 and IL-1Ra were higher than in patients with HFrEF. IL-1 was not detected in stable condition, and differences in IL-1R2 and IL-1Ra concentrations between fractions subsided. Conclusion In ADHF, the differences in the concentrations of IL-1 and endogenous inhibitors of IL-1 signaling, IL-1R2 and IL-1βRa, in patients with HFpEF and HFrEF indicated different severity of the inflammatory response in these fractions and more intense neutralization of IL-1 in patients with HFpEF compared to patients with HFrEF, which should be taken into account in the therapeutic blockade of IL-1.
- Open Access
- 10 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (8) , 6254
Changes in interleukin‑6 levels depending on body mass index in patients with acute decompensated heart failure
Aim. To estimate IL-6 levels in patients with acute decompensated heart failure (ADHF) depending on body mass index (BMI).Material and methods. The study included 110 patients with ADHF. The patients were assigned into 4 groups depending on BMI. The first group included 17 patients with BMI2; the second group, 29 patients with 25≤BMI2; the third group, 33 patients with 30≤BMI2; and the fourth group, 31 patient with BMI ≥35 kg/m2. All patients underwent standard general clinical and biochemical studies. IL-6 levels were determined using monoclonal antibodies. After 1 year of observation, clinical condition of all patients was assessed as stable.Results. IL-6 levels in ADHF patients decreased as BMI increased. The highest IL6 values were recorded in group 1 patients (14,61(8,65; 21,14) pg/ml) and the lowest in group 4 patients (6,34(3,61; 10,17) pg/ml). As BMI increased in groups, the percentage of patients with HFpEF increased (from 12% in group 1 to 40% in group 4). Under stable condition, the intergroup differences between IL-6 were insignificant, with IL-6 levels being lower than in ADHF. A negative correlation was established between IL-6 levels and BMI (r =-0.265, p = 0.006), IL-6 levels and LVEF (r = -0,201, p= 0,040) and between BNP concentrations and BMI (r = -0,486, p < 0,001) in patients with ADHF.Conclusion. In patients with ADHF, an increase in BMI is accompanied by a decrease in circulating IL‑6 levels, which may indicate differences in inflammatory response mechanisms in patients with normal body weight and obesity. Further research will make it possible to develop novel personalized approaches to the treatment of heart failure in overweight and obese patients.
- 10 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (8) , 6254
Open AccessChanges in interleukin‑6 levels depending on body mass index in patients with acute decompensated heart failure
Aim. To estimate IL-6 levels in patients with acute decompensated heart failure (ADHF) depending on body mass index (BMI).Material and methods. The study included 110 patients with ADHF. The patients were assigned into 4 groups depending on BMI. The first group included 17 patients with BMI2; the second group, 29 patients with 25≤BMI2; the third group, 33 patients with 30≤BMI2; and the fourth group, 31 patient with BMI ≥35 kg/m2. All patients underwent standard general clinical and biochemical studies. IL-6 levels were determined using monoclonal antibodies. After 1 year of observation, clinical condition of all patients was assessed as stable.Results. IL-6 levels in ADHF patients decreased as BMI increased. The highest IL6 values were recorded in group 1 patients (14,61(8,65; 21,14) pg/ml) and the lowest in group 4 patients (6,34(3,61; 10,17) pg/ml). As BMI increased in groups, the percentage of patients with HFpEF increased (from 12% in group 1 to 40% in group 4). Under stable condition, the intergroup differences between IL-6 were insignificant, with IL-6 levels being lower than in ADHF. A negative correlation was established between IL-6 levels and BMI (r =-0.265, p = 0.006), IL-6 levels and LVEF (r = -0,201, p= 0,040) and between BNP concentrations and BMI (r = -0,486, p < 0,001) in patients with ADHF.Conclusion. In patients with ADHF, an increase in BMI is accompanied by a decrease in circulating IL‑6 levels, which may indicate differences in inflammatory response mechanisms in patients with normal body weight and obesity. Further research will make it possible to develop novel personalized approaches to the treatment of heart failure in overweight and obese patients.
- Open Access
- 31 March 2024
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 64 (3) , 34-39
Interleukin 6 Signalling in Heart Failure With Preserved and Reduced Ejection Fraction
Aim . Identification of interleukin-6 (IL-6) signaling pathways in patients with chronic heart failure (CHF). Material and methods . The diversity of IL-6 effects is due to the presence of classical signaling and trans-signaling pathways. The study included 164 patients with CHF hospitalized for acute decompensated heart failure (ADHF), of which 129 had reduced left ventricular ejection fraction (HFrEF), and 35 had preserved ejection fraction (HFpEF). Blood concentrations of IL-6, soluble IL-6 receptor (sIL-6R), soluble transducer protein gp130 (sgp130), and high-sensitivity C-reactive protein (hsCRP) were measured. Results . Patients with HFpEF had lower concentrations of IL-6 (6.15 [2.78, 10.65] pg/ml) and hsCRP (11.27 [5.84, 24.40] mg/ml) than patients with HFrEF (9.20 [4.70; 15.62] pg/ml and 17.23 [8.70; 34.51 mg/ml], respectively). In contrast, concentrations of rIL-6R were higher in HFpEF (59.06 [40.00; 75.85] ng/ml) than in HFrEF (49.15 [38.20; 64.89] ng/ml). Concentrations of sgp130 were not significantly different. In patients with HFrEF, positive correlations were found between the concentrations of IL-6 and hsCRP, IL-6 and rIL-6R, and IL-6 and sgp130, while in patients with HFpEF, there was a correlation only between IL-6 and hsCRP, which appeared stronger than in patients with HFrEF (r=0.698; pConclusion . Classical IL-6 signaling and trans-signaling are expressed to different degrees in patients with HFrEF and HFpEF in ADHF. The results of the study supplement the existing knowledge about the pathogenesis of inflammation in CHF and may contribute to the development of new methods and approaches to the treatment of the disease.
- 31 March 2024
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 64 (3) , 34-39
Open AccessInterleukin 6 Signalling in Heart Failure With Preserved and Reduced Ejection Fraction
Aim . Identification of interleukin-6 (IL-6) signaling pathways in patients with chronic heart failure (CHF). Material and methods . The diversity of IL-6 effects is due to the presence of classical signaling and trans-signaling pathways. The study included 164 patients with CHF hospitalized for acute decompensated heart failure (ADHF), of which 129 had reduced left ventricular ejection fraction (HFrEF), and 35 had preserved ejection fraction (HFpEF). Blood concentrations of IL-6, soluble IL-6 receptor (sIL-6R), soluble transducer protein gp130 (sgp130), and high-sensitivity C-reactive protein (hsCRP) were measured. Results . Patients with HFpEF had lower concentrations of IL-6 (6.15 [2.78, 10.65] pg/ml) and hsCRP (11.27 [5.84, 24.40] mg/ml) than patients with HFrEF (9.20 [4.70; 15.62] pg/ml and 17.23 [8.70; 34.51 mg/ml], respectively). In contrast, concentrations of rIL-6R were higher in HFpEF (59.06 [40.00; 75.85] ng/ml) than in HFrEF (49.15 [38.20; 64.89] ng/ml). Concentrations of sgp130 were not significantly different. In patients with HFrEF, positive correlations were found between the concentrations of IL-6 and hsCRP, IL-6 and rIL-6R, and IL-6 and sgp130, while in patients with HFpEF, there was a correlation only between IL-6 and hsCRP, which appeared stronger than in patients with HFrEF (r=0.698; pConclusion . Classical IL-6 signaling and trans-signaling are expressed to different degrees in patients with HFrEF and HFpEF in ADHF. The results of the study supplement the existing knowledge about the pathogenesis of inflammation in CHF and may contribute to the development of new methods and approaches to the treatment of the disease.
- 1 January 2023
- Published by Publishing House RAMS in Bulletin of Experimental Biology and Medicine
- Vol. 176 (10) , 417-421
Ratios between the levels of interleukin 18, free interleukin 18 and interleukin 18 binding protein depending on severity and outcome of COVID-19
- 1 January 2023
- Published by Publishing House RAMS in Bulletin of Experimental Biology and Medicine
- Vol. 176 (10) , 417-421
Ratios between the levels of interleukin 18, free interleukin 18 and interleukin 18 binding protein depending on severity and outcome of COVID-19
- 17 February 2022
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 172 (4) , 407-409
Extracellular Matrix Components of Rat Lungs after Direct and Indirect Lung Injury
We studied the effects of direct intratracheal and indirect intravenous administration of pathogen on the concentrations of types I, III, and IV collagens and fibronectin and expression of the corresponding genes at the early stages of LPS-induced lung injury. Direct and indirect administration of LPS increased the level of type III collagen and decreased the expression of genes encoding types I and III collagens. Expression of type IV collagen remained unchanged. Considerable decrease in fibronectin gene expression was observed after direct LPS administration. Thus, changes in the extracellular matrix of the lungs at the early stages of acute lung injury differ depending on the way of pathogen administration.
- 17 February 2022
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 172 (4) , 407-409
Extracellular Matrix Components of Rat Lungs after Direct and Indirect Lung Injury
We studied the effects of direct intratracheal and indirect intravenous administration of pathogen on the concentrations of types I, III, and IV collagens and fibronectin and expression of the corresponding genes at the early stages of LPS-induced lung injury. Direct and indirect administration of LPS increased the level of type III collagen and decreased the expression of genes encoding types I and III collagens. Expression of type IV collagen remained unchanged. Considerable decrease in fibronectin gene expression was observed after direct LPS administration. Thus, changes in the extracellular matrix of the lungs at the early stages of acute lung injury differ depending on the way of pathogen administration.
- Open Access
- 15 November 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (11) , 1389-1394
Pro-inflammatory cytokines in chronic cardiac failure: state of problem
Systemic inflammation is characterized by the induction of pro-inflammatory cytokines, the increased level of which in the blood of patients with chronic heart failure (CHF) correlates with unfavorable clinical outcomes. However, it is unclear whether pro-inflammatory cytokines are the cause or the consequence of the disease progression. CHF with preserved ejection fraction and CHF with reduced ejection fraction demonstrate different inflammatory features, which suggests different degrees of pro-inflammatory pathway activation. The review deals with participation of pro-inflammatory cytokines in pathophysiological processes of CHF development, emphasizing the role of interleukin-6 activation and the effects of accompanying diseases on the course of systemic inflammation. The search for new approaches to prevention and therapy of CHF remains actual. The review presents the results of clinical trials of targeted anti-cytokine therapy which have revealed difficulties in controlling inflammation under the conditions of CHF. Identification of specific pro-inflammatory pathways in CHF pathogenesis will allow one to control inflammatory cascades, thus providing a prospective therapeutic strategy.
- 15 November 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (11) , 1389-1394
Open AccessPro-inflammatory cytokines in chronic cardiac failure: state of problem
Systemic inflammation is characterized by the induction of pro-inflammatory cytokines, the increased level of which in the blood of patients with chronic heart failure (CHF) correlates with unfavorable clinical outcomes. However, it is unclear whether pro-inflammatory cytokines are the cause or the consequence of the disease progression. CHF with preserved ejection fraction and CHF with reduced ejection fraction demonstrate different inflammatory features, which suggests different degrees of pro-inflammatory pathway activation. The review deals with participation of pro-inflammatory cytokines in pathophysiological processes of CHF development, emphasizing the role of interleukin-6 activation and the effects of accompanying diseases on the course of systemic inflammation. The search for new approaches to prevention and therapy of CHF remains actual. The review presents the results of clinical trials of targeted anti-cytokine therapy which have revealed difficulties in controlling inflammation under the conditions of CHF. Identification of specific pro-inflammatory pathways in CHF pathogenesis will allow one to control inflammatory cascades, thus providing a prospective therapeutic strategy.
- Open Access
- 24 March 2021
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 10 (1) , 6-15
Diagnostic prediction models of stratifying chronic heart failure patients based on the underlying disease
Aim. To develop classification criteria for stratifying congestive heart failure (CHF) patients based on the underlying disease.Methods. 61 patients with CHF were recruited in a study. All patients were assigned to three groups according to the underlying disease: patients with coronary artery disease (CAD) (n = 29), patients with arterial hypertension (AH) (n = 19), and those present with dilated cardiomyopathy (DCM) (n = 13). Patients underwent routine clinical examination. Biochemical and inflammatory markers (IL-6, its soluble receptor sIL-6R, and sgp130) were measured in all patients. The Mann-Whitney U test, the Kruskal-Wallis H test, the Pearson χ2 test, and Fischer exact test were used to analyze the selected variables. Discriminant analysis was used for generating prediction models. The quality of the models was evaluated with the ROC analysis.Results. Statistically significant variables identified by the pairwise comparison of patients with CAD and AH, CAD and DCM, AH and DCM were included in the discriminant analysis along with clinically valid parameters. Clinical prediction models of stratifying patients to different etiological groups were based on these parameters. The optimal cut-off values were determined for each model. The area under the ROC curve (AUC) was used to evaluate the quality of the model. The AUC value for CAD and AH groups was 1, for AH and DCM - 72±0.024, and for CAD and DCM - 0.907±0.053.Conclusion. Diagnostic prediction models were developed using the discriminant analysis. These models allow stratifying CHF patients according to the underlying disease (CAD, AH, and DCM). The ROC curves have confirmed the good classifying quality of the models.
- 24 March 2021
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 10 (1) , 6-15
Open AccessDiagnostic prediction models of stratifying chronic heart failure patients based on the underlying disease
Aim. To develop classification criteria for stratifying congestive heart failure (CHF) patients based on the underlying disease.Methods. 61 patients with CHF were recruited in a study. All patients were assigned to three groups according to the underlying disease: patients with coronary artery disease (CAD) (n = 29), patients with arterial hypertension (AH) (n = 19), and those present with dilated cardiomyopathy (DCM) (n = 13). Patients underwent routine clinical examination. Biochemical and inflammatory markers (IL-6, its soluble receptor sIL-6R, and sgp130) were measured in all patients. The Mann-Whitney U test, the Kruskal-Wallis H test, the Pearson χ2 test, and Fischer exact test were used to analyze the selected variables. Discriminant analysis was used for generating prediction models. The quality of the models was evaluated with the ROC analysis.Results. Statistically significant variables identified by the pairwise comparison of patients with CAD and AH, CAD and DCM, AH and DCM were included in the discriminant analysis along with clinically valid parameters. Clinical prediction models of stratifying patients to different etiological groups were based on these parameters. The optimal cut-off values were determined for each model. The area under the ROC curve (AUC) was used to evaluate the quality of the model. The AUC value for CAD and AH groups was 1, for AH and DCM - 72±0.024, and for CAD and DCM - 0.907±0.053.Conclusion. Diagnostic prediction models were developed using the discriminant analysis. These models allow stratifying CHF patients according to the underlying disease (CAD, AH, and DCM). The ROC curves have confirmed the good classifying quality of the models.
- 1 January 2021
- Published by Publishing House RAMS in Bulletin of Experimental Biology and Medicine
- Vol. 172 (10) , 412-415
Components of rat lung extracellular matrix in direct and indirect lung injury
- 1 January 2021
- Published by Publishing House RAMS in Bulletin of Experimental Biology and Medicine
- Vol. 172 (10) , 412-415
Components of rat lung extracellular matrix in direct and indirect lung injury